Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 138

1.

Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.

Yu B, Liu W, Yu WM, Loh ML, Alter S, Guvench O, Mackerell AD Jr, Tang LD, Qu CK.

Mol Cancer Ther. 2013 Sep;12(9):1738-48. doi: 10.1158/1535-7163.MCT-13-0049-T. Epub 2013 Jul 3.

2.

Identification of cryptotanshinone as an inhibitor of oncogenic protein tyrosine phosphatase SHP2 (PTPN11).

Liu W, Yu B, Xu G, Xu WR, Loh ML, Tang LD, Qu CK.

J Med Chem. 2013 Sep 26;56(18):7212-21. doi: 10.1021/jm400474r. Epub 2013 Sep 4.

3.

Salicylic acid based small molecule inhibitor for the oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2).

Zhang X, He Y, Liu S, Yu Z, Jiang ZX, Yang Z, Dong Y, Nabinger SC, Wu L, Gunawan AM, Wang L, Chan RJ, Zhang ZY.

J Med Chem. 2010 Mar 25;53(6):2482-93. doi: 10.1021/jm901645u.

4.

Inhibition of cellular Shp2 activity by a methyl ester analog of SPI-112.

Chen L, Pernazza D, Scott LM, Lawrence HR, Ren Y, Luo Y, Wu X, Sung SS, Guida WC, Sebti SM, Lawrence NJ, Wu J.

Biochem Pharmacol. 2010 Sep 15;80(6):801-10. doi: 10.1016/j.bcp.2010.05.019. Epub 2010 May 25.

5.

Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.

Grosskopf S, Eckert C, Arkona C, Radetzki S, Böhm K, Heinemann U, Wolber G, von Kries JP, Birchmeier W, Rademann J.

ChemMedChem. 2015 May;10(5):815-26. doi: 10.1002/cmdc.201500015. Epub 2015 Apr 15.

PMID:
25877780
6.

Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.

Huang WQ, Lin Q, Zhuang X, Cai LL, Ruan RS, Lu ZX, Tzeng CM.

Curr Cancer Drug Targets. 2014;14(6):567-88. Review.

PMID:
25039348
8.

Structural insights into Noonan/LEOPARD syndrome-related mutants of protein-tyrosine phosphatase SHP2 (PTPN11).

Qiu W, Wang X, Romanov V, Hutchinson A, Lin A, Ruzanov M, Battaile KP, Pai EF, Neel BG, Chirgadze NY.

BMC Struct Biol. 2014 Mar 14;14:10. doi: 10.1186/1472-6807-14-10.

9.

Identification of demethylincisterol A3 as a selective inhibitor of protein tyrosine phosphatase Shp2.

Chen C, Liang F, Chen B, Sun Z, Xue T, Yang R, Luo D.

Eur J Pharmacol. 2017 Jan 15;795:124-133. doi: 10.1016/j.ejphar.2016.12.012. Epub 2016 Dec 8.

PMID:
27939989
10.

Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.

Chen YN, LaMarche MJ, Chan HM, Fekkes P, Garcia-Fortanet J, Acker MG, Antonakos B, Chen CH, Chen Z, Cooke VG, Dobson JR, Deng Z, Fei F, Firestone B, Fodor M, Fridrich C, Gao H, Grunenfelder D, Hao HX, Jacob J, Ho S, Hsiao K, Kang ZB, Karki R, Kato M, Larrow J, La Bonte LR, Lenoir F, Liu G, Liu S, Majumdar D, Meyer MJ, Palermo M, Perez L, Pu M, Price E, Quinn C, Shakya S, Shultz MD, Slisz J, Venkatesan K, Wang P, Warmuth M, Williams S, Yang G, Yuan J, Zhang JH, Zhu P, Ramsey T, Keen NJ, Sellers WR, Stams T, Fortin PD.

Nature. 2016 Jul 7;535(7610):148-52. Epub 2016 Jun 29.

PMID:
27362227
11.

Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia.

Müller PJ, Rigbolt KT, Paterok D, Piehler J, Vanselow J, Lasonder E, Andersen JS, Schaper F, Sobota RM.

J Proteomics. 2013 Jun 12;84:132-47. doi: 10.1016/j.jprot.2013.04.005. Epub 2013 Apr 11.

PMID:
23584145
12.

Discovery of a novel shp2 protein tyrosine phosphatase inhibitor.

Chen L, Sung SS, Yip ML, Lawrence HR, Ren Y, Guida WC, Sebti SM, Lawrence NJ, Wu J.

Mol Pharmacol. 2006 Aug;70(2):562-70. Epub 2006 May 22.

13.

SHP2 sails from physiology to pathology.

Tajan M, de Rocca Serra A, Valet P, Edouard T, Yart A.

Eur J Med Genet. 2015 Oct;58(10):509-25. doi: 10.1016/j.ejmg.2015.08.005. Epub 2015 Sep 2. Review.

PMID:
26341048
14.
15.

A small molecule inhibitor that stabilizes the autoinhibited conformation of the oncogenic tyrosine phosphatase SHP2.

Wu X, Xu G, Li X, Xu W, Li Q, Liu W, Kirby KA, Loh ML, Li J, Sarafianos SG, Qu CK.

J Med Chem. 2018 Nov 20. doi: 10.1021/acs.jmedchem.8b00513. [Epub ahead of print]

PMID:
30457860
16.
17.

Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.

Bentires-Alj M, Paez JG, David FS, Keilhack H, Halmos B, Naoki K, Maris JM, Richardson A, Bardelli A, Sugarbaker DJ, Richards WG, Du J, Girard L, Minna JD, Loh ML, Fisher DE, Velculescu VE, Vogelstein B, Meyerson M, Sellers WR, Neel BG.

Cancer Res. 2004 Dec 15;64(24):8816-20.

18.

Structural mechanism associated with domain opening in gain-of-function mutations in SHP2 phosphatase.

Darian E, Guvench O, Yu B, Qu CK, MacKerell AD Jr.

Proteins. 2011 May;79(5):1573-88. doi: 10.1002/prot.22984. Epub 2011 Mar 1.

19.

Non-lineage/stage-restricted effects of a gain-of-function mutation in tyrosine phosphatase Ptpn11 (Shp2) on malignant transformation of hematopoietic cells.

Xu D, Liu X, Yu WM, Meyerson HJ, Guo C, Gerson SL, Qu CK.

J Exp Med. 2011 Sep 26;208(10):1977-88. doi: 10.1084/jem.20110450. Epub 2011 Sep 19.

20.

New approaches to prevent LEOPARD syndrome-associated cardiac hypertrophy by specifically targeting Shp2-dependent signaling.

Schramm C, Edwards MA, Krenz M.

J Biol Chem. 2013 Jun 21;288(25):18335-44. doi: 10.1074/jbc.M113.483800. Epub 2013 May 14.

Supplemental Content

Support Center